fda glp-1 compounding enforcement september 2025 Safe use of compounded GLP products FDA is short-sighted on compounding
Description
doi: 10.1016/0014-5793(82)80709-6
Gradual Weight Loss and Muscle Maintenance For those using GLP-1 drugs primarily for weight loss, microdosing might offer a more gradual weight loss experience, which some individuals believe helps preserve muscle mass
larger residual deviance values indicate poorer model fit for that arm in the per-arm models
The combination yields greater weight loss than either agent alone, with mean reductions in body weight of approximately 20.4% over 68 weeks in non-diabetic adults and 13.7% in those with type 2 diabetesfar exceeding placebo and monotherapy arms
